Biosimilar erythropoiesis‐stimulating agents are an effective and safe option for the management of myelofibrosis‐related anemia

Objectives Erythropoiesis‐stimulating agents (ESA) have an established role in treating anemia in hematological malignancies. However, their role, particularly biosimilar ESA (B‐ESA), in myelofibrosis (MF) is not well established. Methods This study retrospectively collected data on 96 MF patients t...

Full description

Saved in:
Bibliographic Details
Published in:European journal of haematology 2023-04, Vol.110 (4), p.354-361
Main Authors: Inzoli, Elena, Crisà, Elena, Pugliese, Novella, Civettini, Ivan, Lanzarone, Giuseppe, Castelli, Andrea, Martinelli, Vincenzo, Montelisciani, Laura, Antolini, Laura, Gambacorti‐Passerini, Carlo, Elli, Elena Maria
Format: Article
Language:English
Subjects:
Aged
Anemia
Anemia - drug therapy
Biological products
biosimilar pharmaceuticals
Biosimilar Pharmaceuticals - therapeutic use
Erythropoiesis
erythropoiesis‐stimulating agents
Ferritin
Hematinics - adverse effects
Hemoglobins
Humans
Janus kinase inhibitors
Leukemia
Malignancy
Multivariate analysis
Myelofibrosis
outcome
Patients
Primary Myelofibrosis - drug therapy
Retrospective Studies
Survival
Toxicity
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives Erythropoiesis‐stimulating agents (ESA) have an established role in treating anemia in hematological malignancies. However, their role, particularly biosimilar ESA (B‐ESA), in myelofibrosis (MF) is not well established. Methods This study retrospectively collected data on 96 MF patients treated with B‐ESA (alpha/zeta) for the management of anemia to assess safety, efficacy (anemia response [AR]), and survival. Results Seventy‐seven patients (80%) obtained AR. The median time to AR was 2.5 months. In multivariate analysis, significant predictive factors of AR were transfusion independency (p = .006) and ferritin levels  8.5 g/dl (p = .047) at baseline were significantly associated with improved survival, with a trend for longer survival in AR patients (p = .06). Conclusions B‐ESA seems to be an effective and well‐tolerated option for anemia treatment in the MF setting. This strategy deserves further clinical investigation.
ISSN:0902-4441
1600-0609
DOI:10.1111/ejh.13910